Show simple item record

dc.contributor.authorHong, Kimberly N
dc.contributor.authorEshraghian, Emily A
dc.contributor.authorArad, Michael
dc.contributor.authorArgirò, Alessia
dc.contributor.authorBrambatti, Michela
dc.contributor.authorBui, Quan
dc.contributor.authorCaspi, Oren
dc.contributor.authorde Frutos, Fernando
dc.contributor.authorGreenberg, Barry
dc.contributor.authorHo, Carolyn Y
dc.contributor.authorKaski, Juan Pablo
dc.contributor.authorOlivotto, Iacopo
dc.contributor.authorTaylor, Matthew R G
dc.contributor.authorYesso, Abigail
dc.contributor.authorGarcia-Pavia, Pablo 
dc.contributor.authorAdler, Eric D
dc.date.accessioned2024-05-10T08:34:27Z
dc.date.available2024-05-10T08:34:27Z
dc.date.issued2023-10-17
dc.identifier.citationJ Am Coll Cardiol. 2023 Oct 17;82(16):1628-1647.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19344
dc.description.abstractDanon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of function variants in the LAMP2 gene and is among the most severe and penetrant of the genetic cardiomyopathies. Most patients with Danon disease will experience symptomatic heart failure. Male individuals generally present earlier than women and die of either heart failure or arrhythmia or receive a heart transplant by the third decade of life. Herein, the authors review the differential diagnosis of Danon disease, diagnostic criteria, natural history, management recommendations, and recent advances in treatment of this increasingly recognized and extremely morbid cardiomyopathy.es_ES
dc.description.sponsorshipThis paper represents the consensus opinions of the authors, borne from an International Advisory Board meeting funded by Rocket Pharmaceuticals, who also provided support for development of the Central Illustration. Dr Garcia-Pavia has received consulting fees from Lexeo Therapeutics and Rocket Pharmaceuticals. Dr Adler has served as Chief Science Officer for Lexeo Therapeutics; and has served as an advisor for Rocket Pharmaceuticals.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshGlycogen Storage Disease Type IIb es_ES
dc.subject.meshCardiomyopathies es_ES
dc.subject.meshHeart Failure es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshFemale es_ES
dc.subject.meshDiagnosis, Differential es_ES
dc.subject.meshConsensus es_ES
dc.subject.meshLysosomal-Associated Membrane Protein 2 es_ES
dc.titleInternational Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review.es_ES
dc.typereview articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID37821174es_ES
dc.format.volume82es_ES
dc.format.number16es_ES
dc.format.page1628es_ES
dc.identifier.doi10.1016/j.jacc.2023.08.014es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1558-3597es_ES
dc.relation.publisherversion10.1016/j.jacc.2023.08.014es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional